Abstract: An object of the invention is to provide a comprehensive biomarker for artery lesions, and diabetes mellitus, heart disease, cerebrovascular disorder, cancer, kidney disease, etc., whose onset and progress can be suppressed by health care such as early diagnosis. The inventors have found that the object can be attained by determining the level of an antibody to protein KIAA0513 or a portion of the protein, the antibody being potentially present in a body fluid sample collected from a living body; and acquiring data showing a rise in the antibody level as data showing the presence of an artery lesion or the potential or actual presence of cerebrovascular or cardiovascular disorder, diabetes mellitus, chronic kidney disease, or a solid cancer.

Abstract: To provide an electrode for an electricity storage device, which electrode employs a porous conductor having conductive nanostructures formed on its surface and makes it possible to provide a less expensive electricity storage device having a high discharge capacity and high charge/discharge cycle resistance. A porous conductor which is used as an electrode for an electricity storage device has a plurality of conductive nanostructures on a surface of the porous conductor.

Abstract: The invention tracks and automatically evaluates plant traits of “individuals of plant canopy” in a growth process of a germination period (from sowing until immediately prior to primary seedling culture), at a plant factory with artificial lighting. Specifically, a two-dimensional distribution of the plant traits is calculated by non-destructively and continuously measuring plant trait information in the growth process of the germination period, on the basis of image information 2a, environmental factor information 2b, genetic characteristic information 2c, and management information 2d.

Abstract: A biological state monitoring system (100) for monitoring a biological state of a subject on a bed (BD) over a predetermined monitoring period, includes: at least one load detector (11, 12, 13, 14) configured to detect a load of the subject on the bed; and a respiratory rate estimating unit (34) configured to successively obtain and output estimated values of a respiratory rate of the subject, based on a temporal variation of a detection value of the load detector. The monitoring period includes a body motion period in which the subject has a body motion, and a resting period in which the subject merely performs a respiration.

Abstract: A sightline-position determination device includes: a sightline-position input unit to which a position of a sightline of a user is inputted; a determination region setting unit which sets a determination region; a determination unit which determines whether or not the position of the sightline inputted from the sightline-position input unit falls within the determination region; and an output unit which outputs feedback to the user when the determination unit has determined that the position of the sightline falls within the determination region.

Abstract: A method for detecting anti-deoxyhypusine synthase autoantibody in a subject, wherein the method includes detecting, in a blood, serum, or plasma sample from a test subject with digestive system cancer, the amount of anti-deoxyhypusine synthase autoantibody, wherein the autoantibody is able to bind to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

Abstract: The present invention provides an antibody or a fragment thereof, which specifically binds to a 6-sulfosialyl Lewis X glycan, where the binding requires fucose, a sulfate group, and a sialic acid that form the 6-sulfosialyl Lewis X glycan.

Abstract: An object of the present invention is to provide an external pharmaceutical composition that imparts light stability to a ?-blocker (particularly propranolol hydrochloride) and is excellent in the balance between transdermal absorbability and skin retention, and the present invention provides a complex composed of a water-soluble ?-blocker and lecithin, a method for producing the complex, an external pharmaceutical composition containing the complex, and the like. The complex or a dispersion in oil containing the complex is applied to an existing pharmaceutical external preparation formulation (for example, W/O type cream), and a complex containing a ?-blocker is allowed to be present in the O phase, thereby avoiding contact with water or dissolved oxygen and reducing the risk of photolysis.

Abstract: A determination device includes an acquisition unit, a first determination unit, a second determination unit, and an output unit. The acquisition unit is configured to acquire a sightline direction of a user and a sightline direction of at least one facing person facing the user. The first determination unit is configured to determine whether a sightline of the user is directed to the facing person based on the sightline direction of the user acquired by the acquisition unit. The second determination unit is configured to determine whether a sightline of the facing person is directed to the user based on the sightline direction of the facing person acquired by the acquisition unit. The output unit is configured to output a feedback to the user and/or an executor based on a result of a determination of the first determination unit and a result of a determination of the second determination unit.

Abstract: An allergic disease determination method includes contacting probes selected from an allergen and a fragment thereof and a biological sample collected from a subject; detecting a reaction between the probes and an antibody contained in the biological sample; determining a type of the antibody reacted with the probes; inputting data associated with the reaction of each of the at least two types of probes with the antibody and data associated with a type of the bound antibody into a prediction model and acquiring a prediction result; and determining an allergic disease on the basis of the prediction result. The prediction model is a nonlinear model or a model having two or more explanatory variables and two or more terms, the model being created using training data associated with the reaction of at least the probes with the antibody and training data associated with the type of the bound antibody.

Abstract: The present inventors have surprisingly found that a deoxyhypusine synthase (DHPS) gene, which was previously reported to correlate with prostate cancer and cervical cancer, is highly responsive to arteriosclerosis or digestive system cancer, whereby the gene can be used as a desired marker for arteriosclerosis or digestive system cancer. The present invention has been accomplished on the basis of this finding. Specifically, the present invention provides a method for determining arteriosclerosis or digestive system cancer, which method includes detecting expression of a deoxyhypusine synthase gene in a test sample (preferably a blood sample), and determining arteriosclerosis or digestive system cancer of a test subject from which the test sample has been obtained, on the basis of an increase in the gene expression as an index.

Abstract: A liquid composition includes a thiophene polymer; and at least one polymerization component selected from the group including a monomer and an oligomer.

Abstract: A composition for forming a metallic luster film, includes: a thiophene polymer, in which a total content of an Fe atom, a Cu atom, an Mn atom, a Cr atom, and a Ce atom in the composition for forming a metallic luster film is 1500 ppm or less with respect to the thiophene polymer.

Abstract: [Problem] Provided are a production method for a multi-input/multi-output-type genetic switch or a transcription factor, and a multi-input/multi-output-type genetic switch or a transcription factor. [Solving Means] The inventors of the present invention have completed a production method for a multi-input/multi-output-type genetic switch or a transcription factor, essentially including the steps of “fusing two or more transcription factor genes to each other” and “introducing mutations into the fusion-type transcription factor gene,” and have further succeeded in obtaining a multi-input/multi-output-type genetic switch or a transcription factor by the method.

Abstract: Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: A nitrogen-containing carbon material includes carbon atoms, nitrogen atoms, and halogen atoms. The nitrogen-containing carbon material has a ratio of a number of moles of pyridinic nitrogen atoms to a total number of moles of the nitrogen atoms that is higher than 59% and a total content ratio of the nitrogen atoms with respect to the nitrogen-containing carbon material that is 7 at % or higher. The nitrogen-containing carbon material includes a fused polycyclic aromatic moiety formed by condensation of three or more aromatic rings, and the fused polycyclic aromatic moiety includes a partial structure for two pyridinic nitrogen atoms to be linked to each other through two carbon atoms.

Abstract: It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).

Abstract: Provided is a wood processing system including a wood conveying device having a longitudinal direction along one direction in the horizontal direction and being capable of conveying wood along the longitudinal direction; a multi-axis processing machine arranged on one side in the longitudinal direction of the wood conveying device, the multi-axis processing machine including a spindle capable of being attached with a first tool, and a spindle moving device having two or more linear axes perpendicular to one another and two or more rotational axes for moving the spindle; and at least one multi-articulated robot arranged along the wood conveying device on the other side in the longitudinal direction of the wood conveying device, the at least one multi-articulated robot including a wrist capable of being attached with a tool unit including a second tool, and an arm having six or more rotational axes for moving the wrist.

Abstract: A manufacturing method for manufacturing a colored product, where using inkjet heads which are a plurality of color ink heads, and an inkjet head, which is a colorless ink head, a plurality of coloring regions are formed in an overlapping manner in a normal direction, a surface side colored region, which is a region located closest to the surface of the colored product is formed using at least the color ink ejected from any of the inkjet heads, and an inner colored region, which is a region located farther from the surface of the colored product than the surface side colored region is formed using at least the color ink ejected from any of the inkjet heads and the colorless ink ejected from the inkjet head.

Abstract: A thermoelectric conversion element includes: a thermoelectric conversion layer containing a thiophene polymer, in which a peak intensity of a diffraction angle (2?) of 7.9° is 5 times or more a peak intensity of a diffraction angle (2?) of 25.8° in an X-ray diffraction spectrum of the thermoelectric conversion layer.